Skip Navigation Links

Bookmark and Share
CStone received China NMPA IND acceptance for lorlatinib in Chinese patients with ROS1-positive advanced NSCLC

on 10/19/2021
SUZHOU, China, Oct. 20, 2021 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on researching, developing, and commercializing innovative immuno-oncolo...

Full "IntellAsia: Resources" article

Disclaimer | Terms Of Use And Privacy Statement

© Metals News. All rights reserved.